The U.S. Food and Drug Administration (FDA) has agreed to meet with Glafabra Therapeutics to discuss plans for clinical testing of GT-GLA-S03, the company’s gene therapy candidate for Fabry disease. The face-to-face meeting, scheduled for July 16, was arranged through the FDA’s INTERACT program, which allows certain developers…